Announcement on Change of Securities Affairs Representative
Filed with SSE · · 2 pages · Chinese
Shanghai MicuRx Pharmaceutical Co., Ltd. on 6ix
Earlier from Shanghai MicuRx Pharmaceutical
- Announcement on Voluntary Disclosure of Compensation for the Patent Protection Period of the Company's Core Products
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale
- Announcement on Resignation of Directors and Senior Management Members
- Announcement on Transfer of Some of The Company's Wholly-owned Subsidiary Kerui Kaisi's Business To Four Wholly-owned Subsidiaries Including Kangyue Biology, etc.
- Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
Later from Shanghai MicuRx Pharmaceutical
- Announcement on Voluntary Disclosure of the Company Certified as a High-tech Enterprise
- Earnings Preannouncement for 2025
- Announcement on Voluntary Disclosure of Permission Granted by the US for the Initiation of Clinical Trials of MRX-5
- Notice on Convening the 1st Extraordinary General Meeting in 2026
- Announcement on Preliminary Earnings Estimate for 2025
Follow Shanghai MicuRx Pharmaceutical into a list and get an email when it puts out news.
Follow Shanghai MicuRx Pharmaceutical